Medtronic's (MDT) Newest Evolut TAVR System Gets FDA Approval

Medtronic plc (MDT) recently secured the FDA’s approval for the Evolut FX+ transcatheter aortic valve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis. The latest Evolut FX+ TAVR system maintains the valve performance benefits of the legacy Evolut TAVR platform and is designed to facilitate coronary access.The latest development will significantly boost the Coronary & Renal Denervation and Structural Heart & Aortic businesses, which are part of Medtronic’s Cardiovascular por ...